Navigation Links
Enova Medical Launches Exos Corporation

New company offers innovative casting, splinting and bracing technology

ST. PAUL, Minn., Aug. 31 /PRNewswire/ -- Enova Medical Technologies, Inc. of St. Paul, Minn., and Product Innovations, Inc. (P.I.) of Aspen, Colo., are pleased to announce the launch of Exos Corporation, a joint venture company that will develop and commercialize innovative orthopedic support devices.

Exos will focus on the product development and commercialization surrounding its revolutionary, patentpending technology called OrthoFoam(TM) Dry-Heat Thermoformable Splint/Cast/Brace Systems. Taking a composite materials approach to the construction and custom fitting of orthopedic devices, OrthoFoam technology is expected to radically change the practices surrounding external orthopedic casting, splinting and bracing.

"There is considerable market opportunity for this technology, ranging from emergency room splinting to long-term bracing during patient rehabilitation. Our immediate focus is to manufacture and launch our initial OrthoFoam products for upper extremity injuries," said Fariborz Boor Boor, Enova CEO and Exos President/CEO. "Over the next year, we will release additional products for lower extremity injuries and longer-term bracing needs through a variety of clinical venues."

Roger Heegaard, Enova president/COO and Exos board member, explained that Exos delivers on Enova's commitment to bringing life-changing technologies to market. "This venture perfectly illustrates Enova's strategy of fostering a collaborative community of medical professionals that discovers new ideas and quickly turns them into innovative healthcare products," he said. "Exos is the direct result of combining P.I.'s tremendous creative and design capabilities with Enova's skill in bringing revolutionary medical technology ideas to life."

Mark Joseph, P.I. president, developer of the OrthoFoam technology, and Exos board member, is excited to be teaming with Enova. "Together we are turning a good idea into a reality in the marketplace. Exos is our common vision to make a serious difference in a field that we believe is long overdue for new technology. Casting has seen little improvement over the past twenty-five years when compared with other medical fields and we intend to raise it to a new level."

Patents are pending on the OrthoFoam technology. Exos bracing, splinting and casting products will be considered Class I medical devices according to FDA regulations. The first product launch is expected in early 2008.

Enova Medical Technologies, a privately held company, is engaged in the development and commercialization of proprietary medical devices and is an experienced provider of product development, manufacturing, and commercialization services for the medical device industry. From Class I to Class III devices, Enova understands the technical challenges of product design, engineering, research and development, the regulatory steps required to successfully commercialize products, and the marketing and sales efforts needed to move inventory off the shelf. For more information, visit

Product Innovations, a privately held company, was founded in 1982 in Aspen, Colo., and has developed a wide variety of products for the lighting, footwear, outdoor, sporting and ski industries. For more information, visit

SOURCE Enova Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Renovar captures $1.2M for product development
2. Cisco Chairman donates $31 million for UW building renovation
3. Medical College receives $377K to study brain disease
4. Barriers will not stop convergence of medical technologies
5. Medical College team creates website for tracking flu
6. Biomedical engineering conference invites manufacturers
7. Visions: Wade offers straight talk on e-medical records
8. Merge unveils updated medical imaging software
9. Medical College receives $1.4M cancer grant
10. Medical technology firm lands $100K federal grant
11. Doyle outlines spending for Medical College, UWM
Post Your Comments:
(Date:12/1/2015)... 1, 2015 Frost & Sullivan is ... program addresses ways companies can innovate and transform ... --> ... --> ... well as the disrupting factors altering the industry, ...
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 /PRNewswire/ ... announced the addition of the "2016 ... Sales Forecasts, Innovative Technologies, Competitive Strategies, Opportunities ... report to their offering. --> ... the "2016 Europe Cell Surface Markers: ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... announces that its best selling system laboratory animal colony management software solution, ezColony®, ... without investing in on-site IT resources., , Many organizations ...
(Date:12/1/2015)... SUNNYVALE, Calif. , Dec. 1, 2015 ... part of its participation at the Piper Jaffray Healthcare ... later this morning, the Company is reaffirming its outlook ... guidance for 2016, in addition to discussing longer term ... Chairman and Chief Executive Officer.  "We continue to be ...
Breaking Biology Technology:
(Date:11/18/2015)... ALBANY, New York , November 18, 2015 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2021. According to ... bn in 2014 and is anticipated to reach US$29.1 ... 2015 to 2021. North America ...
(Date:11/17/2015)... LIVERMORE, Calif. , Nov. 17, 2015  Vigilant ... has joined its Board of Directors. ... Vigilant,s Board after recently retiring from the partnership at ... owning 107 companies with over $140 Billion in revenue.  ... performance improvement across all the TPG companies, from 1997 ...
(Date:11/12/2015)... 2015  A golden retriever that stayed healthy despite ... has provided a new lead for treating this muscle-wasting ... Institute of MIT and Harvard and the University of ... Cell, pinpoints a protective gene that ... effects. The Boston Children,s lab of Lou Kunkel ...
Breaking Biology News(10 mins):